Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | The impact of bariatric surgery on the outcomes of patients with CML treated with TKIs

Fadi Haddad • 24 Jun 2022
EHA 2022
Chronic Myeloid Leukemia Leukemia

Fadi Haddad, MD, MD Anderson Cancer Center, Houston, TX, discusses the results of a study investigating the impact of bariatric surgery on the outcomes of patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs). Overall, the study found that patients who had bariatric surgery had a worse failure-free survival (FFS), as well as a worse overall survival (OS), and took a longer time to achieve a complete cytogenetic remission (CCyR) and major molecular response (MMR) than patients who had not undergone a bariatric surgery. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Fadi Haddad

2:32
Blinatumomab and ponatinib in newly diagnosed Ph+ ALL: updates from a Phase II trial
Fadi Haddad • 11 Dec 2023
4:49
Dasatinib plus venetoclax in ECP-CML: insights from a Phase II study
Fadi Haddad • 11 Dec 2023
8:36
FLT3 mutational status can change between diagnosis and relapse in patients with AML
Fadi Haddad • 23 Nov 2022
2:51
The emergence of novel antibodies, CAR-T and CAR-NK therapies in AML
Fadi Haddad • 23 Nov 2022

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals